Opus Genetics, Inc.
NASDAQ:IRDBiotechnology
-$0.01 today
- Market cap
- $326.13M
- Beta
- 0.55
- P/E (TTM)
- -33.0
- EPS (TTM)
- -$0.12
Volume 0.75M
Average 0.81M
IRD Net Debt
Total debt minus cash and equivalents; a negative value means the company holds more cash than debt.
Opus Genetics, Inc.NASDAQ: IRD
Net Debt · Q1 FY2026 · quarter ended Mar 2026
Net debt remains negative
Q1 FY2026 net debt was -$34.03M, compared with -$41.79M a year earlier.
Context
- Net debt amounted to 50.9% of total assets at the end of Q1 FY2026, down 35.8 pp from a year earlier.
- Net debt grew in size in 2 of the last 3 fiscal years.
What to watch
Whether net debt keeps rising in the next quarterly balance sheet after a +18.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Debt history
USD · from the balance sheet
- Latest · FY2025
- (45.09M) USD
- Year-over-year change
- -48.7%
| Period | Period end | Net Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (45.09M) | -48.7% |
| FY2024 | 2024-12-31 | (30.32M) | +40.0% |
| FY2023 | 2023-12-31 | (50.5M) | -18.5% |
| FY2022 | 2022-12-31 | (42.63M) | -77.7% |
| FY2021 | 2021-12-31 | (24M) | — |
Net Debt vs competitors
How IRD compares with its peers on the latest reported figures
- IRD's Mar 2026 net debt of -$34.03M is the 9th highest of the 10 companies compared; the peer median is -$17.58M.
- Its year-over-year change of +18.6% is the 4th highest of 10, against a peer median of +10.2%.
- Net debt amounts to 50.9% of total assets for IRD, versus a peer median of 35.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $269.47M | +266.3% | — | 144.5% | |
| Mar 2026 | $80.16M | +12.4% | +29.5% | 40.0% | |
| Mar 2026 | $50.67M | +65.0% | — | 43.1% | |
| Mar 2026 | -$5.84M | +3.5% | — | 19.7% | |
| Mar 2026 | -$17.58M | +38.6% | — | 35.3% | |
| Mar 2026 | -$20.64M | -1680.4% | — | 15.4% | |
| Mar 2026 | -$24.29M | +10.2% | — | 8.9% | |
| Mar 2026 | -$30.67M | -94.2% | — | 84.9% | |
IRDOpus Genetics, Inc. | Mar 2026 | -$34.03M | +18.6% | — | 50.9% |
| Mar 2026 | -$42.41M | -1479.3% | — | 17.7% | |
| Peer median (excluding IRD) | -$17.58M | +10.2% | +29.5% | 35.3% | |
Competitors are the stored peer set for IRD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Opus Genetics, Inc.
NASDAQ:IRD
Intrinsic Alpha fair value
Locked
Current Price
$3.92
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.